Metformin is the world’s most prescribed diabetes drug and one of the most studied longevity compounds in humans. Decades of real-world data show that diabetics on metformin live longer than matched non-diabetic controls — a striking finding that triggered massive interest in its anti-aging properties.
What Does the Research Say?
The TAME Trial (Targeting Aging with Metformin), funded by the American Federation for Aging Research, is the first FDA-accepted clinical trial with “aging” as its primary endpoint — a landmark regulatory shift for the entire longevity field. Metformin activates AMPK (AMP-activated protein kinase), which mimics the effects of caloric restriction at the cellular level, reducing mTOR-C1 signaling, enhancing autophagy, and reducing systemic inflammation.
A 2014 retrospective study by Bannister et al. found type 2 diabetics on metformin had 15% lower all-cause mortality than matched non-diabetic controls — controlling for the fact that the diabetics had a disease that would be expected to shorten life. Metformin also appears to reduce cancer incidence, particularly colorectal and breast cancers, across multiple large observational studies.
Key Findings
- Diabetics on metformin outlive matched non-diabetic controls in large epidemiological studies
- AMPK activation mimics caloric restriction at the molecular level
- Reduces cancer risk, particularly colorectal cancer, by 20–40% in observational data
- TAME Trial will provide the first definitive human longevity endpoint data for any drug
Practical Takeaway
Metformin is available by prescription for diabetes and pre-diabetes. For longevity use off-label, doses typically range from 500–1000mg/day with meals. It reduces vitamin B12 absorption — supplementation is recommended. Some longevity physicians advise against taking it on exercise days as it may blunt certain training adaptations.